Pipeline

Yellow fever (YF) is caused by the transmission of the yellow fever (YF) virus via the bite of an infected mosquito.

YF occurs in most of sub-Saharan Africa and tropical South America, where it is endemic and intermittently epidemic.

YF vaccination is required for travelers to certain countries and is recommended for all travelers to areas subject to endemic and epidemic disease (WHO).

Annually, and despite the availability of an effective vaccine, an estimated 200 000 cases of yellow fever with ~ 30 000 deaths occur (CDC).

No antiviral drugs are available for the treatment of YF, treatment is directed at symptomatic relief or life-saving interventions.

AstriVax candidate thermostable YF vaccine is the basis of the PLLAV platform technology and offers in addition the possibility to create dual vaccines.

Rabies is a preventable viral disease most often transmitted through the bite or scratch of a rabid animal. The rabies virus infects the central nervous system of mammals, ultimately causing disease in the brain and death.

While rabies is a preventable disease (through pre-exposure prophylaxis and/or post-exposure prophylaxis), an estimated 59 000 people die annually from the disease around the world (CDC).

AstriVax’ candidate thermostable rabies vaccine offers dual protection (e.g. also YF protection) and does so with fewer doses given than currently available vaccines

Hepatitis B is a condition caused by the hepatitis B virus (HBV). The virus can cause both acute and chronic disease.

Chronic hepatitis B (CHB) is a major public health problem.

WHO estimates that ~ 300 million people are living with chronic hepatitis B infection, with 1.5 million new infections each year and 820 000 deaths per year (mostly from cirrhosis and hepatocellular carcinoma) (WHO).

Antiviral therapy is effective in controlling the disease but does typically not allow to cure the infection. Hence life-long antiviral therapy is required.

AstriVax’ candidate CHB therapeutic vaccine, that efficiently induces specific CD8+ T-cells is expected to be a promising component in of a combination therapy that may lead to a functional cure.

Persistent human papillomavirus (HPV) infection is a primary cause of precancerous cervical lesions, which can progress to cervical cancer. Virtually all cervical cancer cases are attributed to HPV.

In high-income countries, between 50% and 79% of women will contract a genital HPV infection during their lifetime, with approximately 40% becoming infected within the first two years of sexual activity (WHO).

Despite the availability of effective vaccines for over a decade, around 4% of individuals still carry high-risk HPV types 16 and 18, which are strongly associated with cervical as well as head and neck cancers.

Cervical cancer is preventable through screening and curable when detected early and treated appropriately. Nevertheless, it remains one of the most prevalent and lethal cancers among women globally.

The development of therapeutic vaccines for HPV could significantly improve current prevention and treatment strategies for cervical cancer. These vaccines could simplify treatment, reduce loss-to-follow-up, and increase the proportion of women effectively treated after a positive test result (WHO).

AstriVax HPV immune therapy is specifically designed to efficiently induce CD8+ T-cells, aiming to treat precancerous lesions and eliminate persistent infections.